Industry Expertise

Achelous Partners specializes in the life science and healthcare sector. As a team, we grasp the key drivers shaping each individual segment of the life science and healthcare sector, including, but not limited to:
Biotechnology
  • Therapeutics
  • Diagnostics
  • Medical Devices
  • Orthopedics
  • Genomics and Proteomics
  • Enzymes
  • Agricultural
  • Biogenerics
  • Novel Production Processes
Pharmaceuticals
  • Drug Discovery through Commercialization
  • Specialty Pharma & Drug Delivery
  • Generics
Research Tools & Services
  • Bioinformatics/Systems Biology
  • Biopharmaceutical Ingredients/Reagents
  • Drug Discovery Tools, Arrays and Assay Kits
  • Separations and Purification Systems
  • Benchtop Instruments
  • Contract Services: Discovery, Clinical Trials & Manufacturing
Healthcare
  • Diagnostic/Pathology Services
  • Professional and Consumer Health Products
  • Blood Plasma Collection
  • Infection Control/Sterilization
  • Surgical Instruments
  • Dental Products
  • Veterinary Health
  • Nutraceuticals/OTC Products

As a team, in addition to specializing in healthcare and life sciences, we have also worked with global companies across a number of other industries including software and IT, chemicals, financial services, defense, telecommunications, electronics, energy, mining, and manufacturing.

As a team, in addition to specializing in healthcare and life sciences, we have also worked with global companies across a number of other industries including software and IT, chemicals, financial services, defense, telecommunications, electronics, energy, mining, and manufacturing.

Recent News

June 12, 2024
Prof. Dr. Sergi X. Trilla joins Achelous Partners as European Representative

June 12, 2024
Achelous Partners Advises Curia on its announced sale of a US CDMO site to Siegfried

April 22, 2024
Achelous Partners Advises A4P Consulting Ltd on its sale to LabConnect

  • June 2024
    Wisconsin CDMO site is being acquired by
    The undersigned acted as financial advisor to Curia Global Inc.
  • April 2024
    has been acquired by
    The undersigned acted as financial advisor to A4P Consulting
  • March 2024
    has been acquired by
    The undersigned acted as financial advisor to Six Degrees Medical
  • December 2023
    has been acquired by
    The undersigned acted as financial advisor to Bio X Cell, LLC
  • November 2023
    has been acquired by
    The undersigned acted as financial advisor to Symbio LLC
  • November 2023
    has been acquired by
    The undersigned acted as financial advisor to Proinnovera, GmbH
  • November 2023
    has been acquired by
    The undersigned acted as financial advisor to Pharmalog, GmbH
  • January 2023
    has been acquired by
    The undersigned acted as financial advisor to ECIR Medical Communications Inc.
  • January 2023
    has been acquired by
    The undersigned acted as financial advisor to Alcedis, GmbH
  • November 2022
    has been acquired by
    The undersigned acted as financial advisor to Expression Systems, LLC
  • October 2022
    has been acquired by
    The undersigned acted as financial advisor to AQW Holdings, Inc. d.b.a. Qfix
  • August 2022
    has been acquired by
    The undersigned acted as financial advisor to AusDiagnostics
  • July 2022
    has been acquired by
    The undersigned acted as financial advisor to Cergentis B.V.
  • July 2022
    has been acquired by
    The undersigned acted as financial advisor to proderm GmbH
  • June 2022
    has been acquired by
    The undersigned acted as financial advisor to SAI MedPartners
  • February 2022
    has acquired
    The undersigned acted as financial advisor to TCP Analytical
  • November 2021
    has been acquired by
    The undersigned acted as financial advisor to Regulatory Compliance Associates Inc.
  • August 2021
    has been acquired by
    The undersigned acted as financial advisor to DRG International Inc.
  • August 2021
    has been acquired by
    The undersigned acted as financial advisor to bioskin GmbH
  • July 2021
    has been acquired by
    The undersigned acted as financial advisor to nanoComposix Holdings, Inc.
  • May 2021
    has been acquired by
    The undersigned acted as financial advisor to Clinical Outcomes Solutions
  • March 2021
    has been acquired by
    The undersigned acted as financial advisor to Diamond Pharma Services
  • February 2021
    has been acquired by
    The undersigned acted as financial advisor to Delphi Genetics
  • October 2020
    has been acquired by
    The undersigned acted as financial advisor to MD Biosciences, Inc.
  • September 2020
    has been acquired by
    The undersigned acted as financial advisor to American Laboratory Products Company, Ltd.
  • September 2020
    has been acquired by
    The undersigned acted as financial advisor to Maetrics LLC
  • August 2020
    has been acquired by
    The undersigned acted as financial advisor to CTK Biotech, Inc.
  • February 2020
    has been acquired by
    The undersigned acted as financial advisor to BresMed Health Solutions Ltd
  • January 2020
    has been acquired by
    The undersigned acted as financial advisor to Statistics Collaborative, Inc.
  • December 2019
    has been acquired by
    The undersigned acted as financial advisor to MLM Medical Labs GmbH
  • October 2019
    has been acquired by
    The undersigned acted as financial advisor to Specialized Medical Services-oncology BV
  • July 2019
    has been acquired by
    The undersigned acted as financial advisor to Eurolyser Diagnostica GmbH
  • July 2019
    has acquired
    The undersigned acted as financial advisor to LifeSpan BioSciences
  • March 2019
    has been acquired by
    The undersigned acted as financial advisor to Quorum Review, Inc.
  • January 2019
    has been acquired by
    The undersigned acted as financial advisor to ProductLife Group
  • January 2019
    has been acquired by
    The undersigned acted as financial advisor to CoreBiome, Inc.
  • October 2018
    has been acquired by
    The undersigned acted as financial advisor to Pennside Partners Ltd.
  • September 2018
    has been acquired by
    The undersigned acted as financial advisor to NovaTec Immundiagnostica GmbH
  • September 2018
    has acquired
    The undersigned acted as financial advisor to Thompson Street Capital Partners
  • September 2018
    has been acquired by
    The undersigned served as financial advisor to HyTest Ltd.
  • July 2018
    has been acquired by
    The undersigned served as financial advisor to Gold Standard Diagnostics Corp.
  • May 2018
    has been acquired by
    The undersigned served as financial advisor to Biovian Oy
  • January 2018
    has been acquired by
    The undersigned served as financial advisor to LifeCodexx AG
  • June 2017
    has been acquired by
    The undersigned acted as financial advisor to Coté Orphan, LLC
  • May 2017
    has been acquired by
    The undersigned acted as financial advisor to PharmaCell B.V.
  • April 2017
    has been acquired by
    The undersigned acted as financial advisor to Emergo Group, Inc.
  • April 2017
    has been acquired by
    The undersigned acted as financial advisor to Calbiotech, Inc.
  • January 2017
    has been acquired by
    The undersigned acted as financial advisor to BioControl Systems, Inc.
  • August 2016
    has been acquired by
    The undersigned acted as financial advisor to SPEware Corporation
  • July 2016
    has acquired
    The undersigned acted as financial advisor to Sharps Compliance Corp.
  • June 2016
    has been acquired by
    The undersigned acted as financial advisor to Cisbio Bioassays
  • December 2015
    has acquired
    The undersigned acted as financial advisor to Abzena plc
  • December 2015
    has acquired
    The undersigned acted as financial adviser to Sharps Compliance Corp.
  • October 2015
    has been acquired by
    The undersigned acted as financial advisor to Kinesis Pharma BV
  • August 2015
    has been acquired by
    The undersigned acted as financial advisor to DIAsource ImmunoAssays SA
  • July 2015
    has acquired
    The undersigned acted as financial advisor to Sharps Compliance Corp.
  • March 2015
    has acquired
    The undersigned acted as financial advisor to Ansell Limited
  • July 2014
    has been acquired by
    The undersigned acted as financial advisor to IBL International Holding BV
  • July 2014
    has been acquired by
    The undersigned served as financial advisor to Phlexglobal Limited
  • June 2014
    has been acquired by
    The undersigned served as financial advisors to Pharmalink Consulting
  • December 2013
    has acquired assets from
    The undersigned acted as advisor to Valeant Pharmaceuticals International
  • August 2013
    has been acquired by
    The undersigned acted as financial advisor to Kirkegaard & Perry Laboratories Inc
  • July 2013
    has been acquired by
    The undersigned acted as financial advisor to The Anson Group LLC
  • July 2013
    has signed a definitive agreement to sell its orthopedic implant assets and business to
    an Apax Partners company The undersigned acted as financial advisor to Austofix Group Limited
  • July 2013
    has been acquired by
    The undersigned acted as financial advisor to Kreatech Holding B.V.
  • July 2013
    has been acquired by
    USD$10,000,000
    The undersigned acted as financial advisor to Matrical Bioscience Inc
  • May 2013
    has been acquired by
    The undersigned acted as advisor to Triangle Biomedical Sciences Inc.
  • August 2012
    has been acquired by
    The undersigned acted as advisor to JSW Life Sciences GmbH
  • March 2012
    has acquired assets from
    US$164M plus up to US$20M in milestones
    The undersigned acted as advisor to Valeant Pharmaceuticals International
  • December 2011
    invests in
    The undersigned acted as advisor to Ansell Limited for the investment
  • August 2010
    has been acquired by
    The undersigned acted as financial advisor to EnviroLogix, Inc.
  • March 2010
    has been acquired by
    USD$59,000,000
    The undersigned acted as financial advisor to Finnzymes Oy
  • December 2009
    has licensed its ReGet® drug delivery system for ophthalmic indications to
    The undersigned acted as financial advisor to BTG olc
  • October 2009
    has been acquired by
    The undersigned acted as financial advisor to Anaspec Inc.
  • August 2009
    has sold its HySolv™ drug delivery technology to
    The undersigned acted as financial advisor to BTG plc
  • January 2009
    has been acquired by
    The undersigned acted as financial advisor to the shareholders of Labcoat Limited
  • December 2008
    has acquired
    The undersigned is acting as financial advisor to Biocompatibles International
  • December 2008
    has acquired
    The undersigned rendered a Fairness Opinion to Affymetrix, Inc.
  • February 2008
    has been acquired by
    The undersigned is acting as financial advisor to Sigma Pharmaceuticals
  • January 2008
    has been acquired by
    The undersigned is acting as financial advisor to Panbio Limited
  • May 2007
    has acquired
    The undersigned acted as financial advisor to Ansell Limited
  • March 2007
    has sold its Human Health point-of-care diagnostic products business to
    The undersigned acted as financial advisor to Agenix Limited
  • February 2007
    Strategic alliance and investment of up to £32,100,000 in
    The undersigned acted as financial advisor to GeneMedix, PLC
  • December 2006
    Announced M&A advisory and restructuring
    The undersigned acted as financial advisor to Panbio Limited
  • December 2006
    has acquired
    The undersigned acted financial advisor to Novozymes A/S
  • August 2006
    has acquired
    The undersigned acted as financial advisor to Meditech Research Limited
  • July 2006
    has acquired Delta Biotechnology Ltd from
    The undersigned acted as financial advisor to Novozymes A/S
  • April 2006
    has assigned IP and granted distribution rights for its Animal Health business to
    The undersigned acted as financial advisor to Agenix Limited
  • October 2005
    M&A advisory and valuation analysis
    The undersigned acted as financial advisor to CogState Limited
  • September 2005
    NASDAQ listing of ADRs (American Depositary Receipts)
    The undersigned acted as advisor to Genetic Technologies Limited
  • June 2005
    NASDAQ listing of ADRs (American Depositary Receipts)
    The undersigned acted as advisor to ChemGenex Pharmarceuticals Limited
  • January 2005
    awarded to
    for its investment banking role in the creation of
  • December 2004
    has been acquired by
    The undersigned acted as financial advisor to AGT Biosciences Ltd.
© 2024 Achelous Partners. 800 Third Avenue, 21st Floor, New York, NY 10022   /   Tel: 212.660.7250   /   Fax: 917.475.9457   /   Privacy Policy   /   site by cleverdesign
Top